Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163253 · ClinicalTrials.gov registry record · Phase 3
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,867
- Enrollment target
NCT01163253: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT01163253 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,867 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (271% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01163253, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,867 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 week
Interventions
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,867 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Why NCT01163253 stopped before completion
NCT01163253 is an interventional study that assigns participants to a tested intervention. Its 2,867 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (271% higher).
The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.
NCT01163253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01163253 about?
NCT01163253 is a clinical study titled "A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis". The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry ...
What is the current status of trial NCT01163253?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,867 participants. The study started on 2010-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01163253?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01163253?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01163253's enrollment target sits among peer trials
2,867 81st of 2000 higher than 1,920 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia